Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 5/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054386 | 0.86 | LMNA (0.55) | LMNATP53MAPTTSHRRAB9A | |
| SCHEMBL3453279 | 0.85 | TP53 (0.48) | LMNATP53MAPTTSHRRAB9A | |
| SCHEMBL8738498 | 0.84 | LMNA (0.44) | LMNATP53MAPTTSHRRAB9A | |
| SCHEMBL13198304 | 0.79 | LMNA (0.51) | LMNATP53MAPTTSHRRAB9A | |
| SCHEMBL20303360 | 0.79 | FLT3 (0.53) | LMNATP53MAPTTSHRRAB9A | |
| SCHEMBL14815795 | 0.79 | LMNA (0.51) | LMNATP53MAPTTSHRRAB9A | |
| SCHEMBL73287 | 0.78 | MAPT (0.55) | LMNATP53MAPTRAB9AATM | |
| SCHEMBL73364 | 0.77 | FLT3 (0.56) | TP53MAPTTSHRFLT3 | |
| SCHEMBL3864616 | 0.77 | LMNA (0.58) | LMNATP53MAPTTSHRRAB9A | |
| SCHEMBL11013003 | 0.76 | MAPT (0.67) | LMNATP53MAPTTSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | LMNA 3036/4885TP53 743/4885MAPT 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.